A detailed history of Bank Of America Corp transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 2,147,425 shares of HOWL stock, worth $4.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,147,425
Previous 1,881,113 14.16%
Holding current value
$4.94 Million
Previous $12.2 Million 57.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.34 - $6.75 $623,170 - $1.8 Million
266,312 Added 14.16%
2,147,425 $5.24 Million
Q1 2024

May 15, 2024

SELL
$3.92 - $7.91 $842,674 - $1.7 Million
-214,968 Reduced 10.26%
1,881,113 $12.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.78 - $4.15 $1.01 Million - $2.35 Million
566,226 Added 37.01%
2,096,081 $8.09 Million
Q2 2023

Aug 14, 2023

SELL
$2.31 - $3.65 $3,714 - $5,869
-1,608 Reduced 0.1%
1,529,855 $4.67 Million
Q1 2023

May 12, 2023

SELL
$1.98 - $4.3 $4,215 - $9,154
-2,129 Reduced 0.14%
1,531,463 $3.98 Million
Q4 2022

Feb 10, 2023

BUY
$1.53 - $4.73 $2.34 Million - $7.24 Million
1,530,114 Added 43994.08%
1,533,592 $3.14 Million
Q3 2022

Nov 14, 2022

BUY
$4.14 - $7.42 $3,245 - $5,817
784 Added 29.1%
3,478 $15,000
Q2 2022

Aug 12, 2022

SELL
$3.43 - $5.98 $67,306 - $117,345
-19,623 Reduced 87.93%
2,694 $11,000
Q1 2022

May 16, 2022

SELL
$3.71 - $12.22 $22,067 - $72,684
-5,948 Reduced 21.04%
22,317 $98,000
Q4 2021

Feb 08, 2022

BUY
$11.48 - $17.65 $317,376 - $487,951
27,646 Added 4466.24%
28,265 $337,000
Q3 2021

Nov 15, 2021

BUY
$13.89 - $20.31 $1,833 - $2,680
132 Added 27.1%
619 $11,000
Q2 2021

Sep 13, 2021

BUY
$11.6 - $17.44 $5,649 - $8,493
487 New
487 $8,000

Others Institutions Holding HOWL

About Werewolf Therapeutics, Inc.


  • Ticker HOWL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,529,400
  • Market Cap $67.9M
  • Description
  • Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...
More about HOWL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.